Tempus AI, a worldwide leader in AI-driven precision medicine, has announced a multi-year partnership with BioNTech SE, a global immunotherapy company at the forefront of cancer and severe disease therapies. Utilizing Tempus’ computational biology expertise and real-world multimodal data, the partnership is designed to enhance BioNTech's oncology research and development pipeline. Utilizing its extensive database, Tempus will offer BioNTech analytical support in order to produce insights into biological mechanisms as part of the collaboration. BioNTech will benefit from this in its pursuit of novel cancer therapies and the enhancement of its clinical oncology pipeline. Integrating AI-driven data analytics with drug development to expedite innovation in personalized medicine is a burgeoning trend, as demonstrated by the partnership.
Ryan Fukushima, Chief Operating Officer of Tempus, emphasized the value of this collaboration: “We are looking forward to collaborating with BioNTech to combine our real-world multimodal data and cutting-edge computational technology to help advance their differentiated oncology pipeline.” Tempus is recognized for its achievements in the application of artificial intelligence to healthcare, particularly in the fields of cancer research and patient care, in order to advance precision medicine. This partnership represents an additional stride in the direction of utilizing real-world data and AI to enhance patient outcomes and expedite the development of next-generation therapies.
